Last reviewed · How we verify
NCT06894537
Echo-guided Percutaneous Electrical Nerve Stimulation of the Femoral Nerve
NA trial testing Experimental (percutaneous echo-guided electrical nerve stimulation) in Health Subjects in 32 participants. Completed in 1 April 2025.
25 March 2025
Quick facts
| Lead sponsor | Universidad Católica San Antonio de Murcia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 32 |
| Start date | 18 March 2025 |
| Primary completion | 25 March 2025 |
| Estimated completion | 1 April 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Experimental (percutaneous echo-guided electrical nerve stimulation)
- Control (placebo) group
Conditions studied
- Health Subjects — all drugs for Health Subjects →
Sponsor
Universidad Católica San Antonio de Murcia
Who can join
Adults 18 to 24, any sex, with Health Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction. Variables such as pain and strength can be modified in the short and medium term by the application of currents. The percutaneous form of percutaneous needle-guided acupuncture can eliminate the impedance of the surrounding tissues that limit the optimal diffusion of the current to the target tissue. It is necessary to objectify the metabolic response of this technique and its effects in terms of strength and metabolic response. Objective. To evaluate the safety and efficacy, in acute and subacute phases, of percutaneous electrical nerve stimulation in healthy subjects. Method. Single-blind randomised clinical study. Thirty-two subjects will be recruited and randomised to the experimental and control groups. The intervention in the experimental group will consist of a percutaneous percutaneous electrical nerve stimulation of the femoral nerve, while in the control group the same intervention will be performed without increasing the intensity of the current. The primary variable will be vertical jump height (My Jump® iOS app) and the secondary variable will be skin temperature (Hikmicro M60 model Hangzhou).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06894537
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Universidad Católica San Antonio de Murcia trials
Trials by the same sponsor.
- NCT07397910 — Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection · NA · not yet recruiting
- NCT07519980 — Xanthigen and Its Impact on Weight and Metabolic Health · NA · recruiting
- NCT07391189 — Healthy Effects of Adapted Aikido in People With Grip Disfunction · NA · recruiting
- NCT07379931 — Evaluating a Liquid Extract of Carob to Improve Blood Sugar in People With Prediabetes · NA · not yet recruiting
- NCT07488000 — Plyometric Exercises During the Winter Pre-season in Sprinters · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06894537 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Católica San Antonio de Murcia
- Last refreshed: 2 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06894537.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing